Lisdexamfetamine (Vyvanse) and Ibuprofen (Advil) Concomitant Use
Concurrent use of lisdexamfetamine (Vyvanse) and ibuprofen (Advil) is generally considered safe, with no clinically important drug–drug interaction identified in major interaction references. [1] Vyvanse prescribing information lists drug interactions that are clinically important for amphetamines (e.g., MAOI antidepressants, serotonergic drugs, CYP2D6 inhibitors, and urinary alkalinizing or acidifying agents), but does not identify ibuprofen among clinically important interaction categories. [2]
Drug Interaction Assessment Framework
Clinically important interactions for Vyvanse focus on: [2]
- MAOI antidepressants (contraindicated due to hypertensive crisis risk). [2]
- Serotonergic drugs (increased serotonin syndrome risk). [2]
- CYP2D6 inhibitors (increased dextroamphetamine exposure and increased risk of serotonin syndrome). [2]
- Urinary alkalinizing agents (increase blood levels of amphetamine). [2]
- Urinary acidifying agents (decrease blood levels of amphetamine). [2]
Practical Safety Considerations With Ibuprofen
Ibuprofen does not have a known mechanism of increasing Vyvanse exposure via the interaction categories listed above. [2] Ibuprofen safety risk is primarily related to NSAID effects such as gastrointestinal irritation/bleeding and kidney effects, which occur independently of Vyvanse. [1]
Monitoring and When to Seek Care
Caution and prompt medical advice are warranted for symptoms suggestive of NSAID harm (e.g., severe stomach pain, black/tarry stools, vomiting blood) or amphetamine-related adverse effects (e.g., chest pain, fainting, severe agitation). [1]
Dose and Administration Approach
Use of the lowest effective ibuprofen dose for the shortest duration is standard for NSAID risk reduction, and spacing doses from Vyvanse is not required for interaction avoidance. [1]
Key Caveats
If additional interacting medicines are present (particularly MAOIs, serotonergic drugs, or CYP2D6 inhibitors), the interaction risk assessment changes and should be reviewed with a pharmacist or prescribing clinician. [2]